---
title: "The concept of controllable nuclear fusion is active, ETERN leads the rise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244615387.md"
description: "The concept of controllable nuclear fusion is active, ETERN rose over 7%, TJSMW rose over 6%, and companies like Juguang Technology, Libat, Prince New Materials, and Hahan Huaton saw significant gains"
datetime: "2025-06-16T02:19:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244615387.md)
  - [en](https://longbridge.com/en/news/244615387.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244615387.md)
generator: "portal-rs"
---

# The concept of controllable nuclear fusion is active, ETERN leads the rise

The concept of controllable nuclear fusion is active, ETERN rose over 7%, TJSMW rose over 6%, and companies like Juguang Technology, Libat, Wangzi New Materials, and Hahan Huaton saw significant gains

### Related Stocks

- [600105.CN](https://longbridge.com/en/quote/600105.CN.md)
- [600577.CN](https://longbridge.com/en/quote/600577.CN.md)
- [301137.CN](https://longbridge.com/en/quote/301137.CN.md)
- [688167.CN](https://longbridge.com/en/quote/688167.CN.md)
- [605167.CN](https://longbridge.com/en/quote/605167.CN.md)
- [002735.CN](https://longbridge.com/en/quote/002735.CN.md)

## Related News & Research

- [REG - RNS - Final Announcement Released](https://longbridge.com/en/news/297944393.md)
- [Air China GAAP EPS of -RMB 0.13, revenue of RMB 89.27B](https://longbridge.com/en/news/297480690.md)
- [Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Update](https://longbridge.com/en/news/297430072.md)
- [Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses](https://longbridge.com/en/news/297996002.md)
- [Adamera Defines IP Anomaly with Minimum Width of 2.8km at Max Copper-Gold Target, South Hedley Project, BC, IP Program Resumes as Wildfire Risks Ease](https://longbridge.com/en/news/297778308.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**